Hostname: page-component-76fb5796d-qxdb6 Total loading time: 0 Render date: 2024-04-26T20:10:14.982Z Has data issue: false hasContentIssue false
  • English
  • Français

Acetylcholine Receptor Antibodies in Myasthenia Gravis: Use of a Qualitative Assay for Diagnostic Purposes

Published online by Cambridge University Press:  18 September 2015

Joel Oger ,
Robin Kaufman  and
Kenneth Berry
Joel Oger*
Affiliation:
Departments of Medicine (Neurology), and the Department of Pathology, University of British Columbia, Vancouver
Robin Kaufman
Affiliation:
Departments of Medicine (Neurology), and the Department of Pathology, University of British Columbia, Vancouver
Kenneth Berry
Affiliation:
Departments of Medicine (Neurology), and the Department of Pathology, University of British Columbia, Vancouver
*
Division of Neurology, University Hospital. 2211 Wesbrook Mall, Vancouver, B.C., Canada V6T 2B5
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We have modified the techniques of Lindstrom and of Tindall to measure serum acetylcholine receptor antibody using human antigen bound to 125I-alpha Bungarotoxin. By using 10 ä1 of serum and precipitating antigen-antibody complexes with an excess of staph A, we found that only one out of 43 patients with clinically diagnosed active generalized Myasthenia Gravis had no antibodies. In pooling these results with the results of tests done for diagnostic purposes we found positive results in 54/55 generalized active MG, 8/21 MG in remission, 16/37 ocular MG and 0/55 healthy controls. Two out of 38 non MG were also positive and their clinical diagnosis of botulism and penicillamine treated rheumatoid arthritis have been confirmed by a one year follow-up. Most of these sera were also tested for reactivity with fetal calf AchR. Six out of 49 samples positive with the human receptor were negative with calf receptor. We conclude that our technique is extremely useful for the diagnosis of Myasthenia Gravis and that fetal calf antigen cannot replace human antigen in the assay.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 14 , Issue 3 , August 1987 , pp. 297 - 302
Copyright
Copyright © Canadian Neurological Sciences Federation 1987

References

REFERENCES

1.Appel, SH, Almon, RR, Levy, N. Acetylcholine receptor antibodies in myasthenia gravis. N Engl J Med 1975; 293: 760–761.CrossRefGoogle ScholarPubMed
2.Lindstrom, JM, Seybold, MF, Lennon, VA, et al. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology 1976; 26: 1054–1059.CrossRefGoogle ScholarPubMed
3.Lefvert, AK, Bergstrom, K, Matell, G, et al. Determination of acetylcholine receptor antibodies in myasthenia gravis: clinical correlates and pathogenic implications. J Neurol Neurosurg Psych 1978; 41: 394–403.CrossRefGoogle Scholar
3.Engel, AG, Lambert, EA, Howard, FM. Immune complexes at the motor end plate in myasthenia gravis. Mayo Clin Proc 1977; 52: 267–280.Google ScholarPubMed
5.Toyka, KV, Drachman, DB, Petonk, A, et al. Myasthenia gravis: passive transferfrom man to mouse. Science 1985; 190:397–399.CrossRefGoogle Scholar
6.Tindall, RSA, Kent, M, Wells, L. A rapid immunosorbant radioimmunoassay for anti-acetylcholine receptor antibody. J 1mm Meth 1981; 45: 1–14.Google ScholarPubMed
7.Kaufman, R, Oger, J. Antibodies to the acetylcholine receptor in myasthenia: comparison between human and fetal calf antigens. Ann NY Acad Sc 1986; 475: 413–414.CrossRefGoogle Scholar
8.Gotti, C, Mantegazza, R, Clementi, F. New antigen for antibody detection in myasthenia gravis. Neurology 1984; 34: 374–377.CrossRefGoogle ScholarPubMed
9.Kautter, DA, Lynt, RK. Clostridium Botulinum In: Compendium of Methods for microbiological examination of food, 2nd edition, Speck, ML, ed. American Public Health Inc., Washington 1984; 468–482.Google Scholar
10.Tindall, RSA. Humoral immunity in MG: clinical correlations of anti-receptorantibody avidity and titer. NYAS 1981; 377:316–329.CrossRefGoogle ScholarPubMed
11.Lefvert, AK. Acetylcholine receptorantibody in myasthenia gravis: purification and characterization. Scand J Imm 1978; 8:525–533.CrossRefGoogle Scholar
12.Vincent, A, Newsom-Davis, J. Acetylcholine receptor antibody as a diagnostic test for myastheni gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg and Psych 1985; 48: 1246–1252.CrossRefGoogle Scholar
13.Garlepp, MJ, Kay, RH, Dawkins, RL. The diagnostic significance of autoantibodies to the acetylcholine receptor. J Neuroimm 1982; 3: 337–350.CrossRefGoogle Scholar
14.Falpius, BW, Miskin, R, Reich, F. Antibodies from myasthenic patients that prevent cholinergic agents from binding to nicotinic receptors. Proc Nat Acad Sc (USA) 1980; 77: 4326–4330.CrossRefGoogle Scholar
15.Lindstrom, J, Campbell, M, Nate, B. Specificities of antibodies to acetylcholine receptor. Muscle and Nerve 1978; 1: 140–145.CrossRefGoogle Scholar